# Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Matthew D. Hellmann,Naiyer A. Rizvi,Jonathan W. Goldman,Scott Gettinger,Hossein Borghaei,Julie R. Brahmer,Neal Ready,David E. Gerber,Laura Q.M. Chow,Rosalyn A. Juergens,Frances A. Shepherd,Scott A. Laurie,William J. Geese,Shruti Agrawal,Tina C. Young,Xuemei Li,Scott Antonia |
| Citations | 964 |
| DOI | 10.1016/s1470-2045(16)30624-6 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/5476941 |
| OpenAlex ID | https://openalex.org/W2560704457 |
| PMID | 27932067 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Matthew D. Hellmann](https://scholariq.org/researchers/matthew-d-hellmann/)
- [Frances A. Shepherd](https://scholariq.org/researchers/frances-a-shepherd/)
- [Xuemei Li](https://scholariq.org/researchers/xuemei-li/)
- [Jonathan W. Goldman](https://scholariq.org/researchers/jonathan-w-goldman/)
- [Julie R. Brahmer](https://scholariq.org/researchers/julie-r-brahmer/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.